E Schraven

411 total citations
23 papers, 347 citations indexed

About

E Schraven is a scholar working on Molecular Biology, Organic Chemistry and Biochemistry. According to data from OpenAlex, E Schraven has authored 23 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 6 papers in Organic Chemistry and 5 papers in Biochemistry. Recurrent topics in E Schraven's work include Amino Acid Enzymes and Metabolism (3 papers), Enzyme function and inhibition (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). E Schraven is often cited by papers focused on Amino Acid Enzymes and Metabolism (3 papers), Enzyme function and inhibition (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). E Schraven collaborates with scholars based in Germany and United Kingdom. E Schraven's co-authors include Karl Schönafinger, Raimund Mannhold, Bernd Jablonka, G Beisenherz, Peter Riederer, Ursula Schindler, Gerald Münch, Reinhard Schinzel, F W Koss and D. Palm and has published in prestigious journals such as Cellular and Molecular Life Sciences, European Journal of Pharmacology and European Journal of Medicinal Chemistry.

In The Last Decade

E Schraven

19 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E Schraven Germany 8 179 78 71 46 31 23 347
David F. Ohlweiler United States 11 135 0.8× 110 1.4× 76 1.1× 11 0.2× 40 1.3× 16 512
Hideo Yoshizumi Japan 16 136 0.8× 213 2.7× 38 0.5× 75 1.6× 71 2.3× 42 677
John V. Burba Canada 6 76 0.4× 150 1.9× 38 0.5× 19 0.4× 31 1.0× 12 357
Gerard. Moinet France 7 62 0.3× 79 1.0× 59 0.8× 132 2.9× 30 1.0× 8 313
D. R. FELLER United States 13 86 0.5× 242 3.1× 76 1.1× 35 0.8× 69 2.2× 47 533
W. L. Bencze Switzerland 10 155 0.9× 135 1.7× 55 0.8× 12 0.3× 31 1.0× 22 493
J. J. Baldwin United States 8 102 0.6× 145 1.9× 29 0.4× 24 0.5× 29 0.9× 13 331
Leon Ellenbogen China 13 39 0.2× 199 2.6× 55 0.8× 39 0.8× 57 1.8× 40 493
Yuchiong Hsuanyu Canada 10 52 0.3× 185 2.4× 99 1.4× 40 0.9× 102 3.3× 19 469
Takashi Kariya Japan 10 91 0.5× 203 2.6× 56 0.8× 9 0.2× 40 1.3× 18 449

Countries citing papers authored by E Schraven

Since Specialization
Citations

This map shows the geographic impact of E Schraven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E Schraven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E Schraven more than expected).

Fields of papers citing papers by E Schraven

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E Schraven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E Schraven. The network helps show where E Schraven may publish in the future.

Co-authorship network of co-authors of E Schraven

This figure shows the co-authorship network connecting the top 25 collaborators of E Schraven. A scholar is included among the top collaborators of E Schraven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E Schraven. E Schraven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Münch, Gerald, E Schraven, Ursula Schindler, et al.. (1994). The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. Journal of Neural Transmission - Parkinsons Disease and Dementia Section. 8(3). 193–208. 62 indexed citations
2.
Wilson, Ian D., J. M. Fromson, H. Paul A. Illing, & E Schraven. (1987). The metabolism of [14C]N-ethoxycarbonyl-3-morpholinosydnonimine (molsidomine) in man. Xenobiotica. 17(1). 93–104. 11 indexed citations
3.
Wilson, Ian D., et al.. (1986). The metabolism of [14C]N-ethoxycarbonyl-3-morpholinosydnonimine (molsidomine) in laboratory animals. Xenobiotica. 16(12). 1117–1128. 9 indexed citations
4.
Dittrich, P., Jerzy Ostrowski, Eckhard Beubler, E Schraven, & W. R. Kukovetz. (1985). [HPLC determination of troxerutin in plasma and urine following oral administration in man].. PubMed. 35(4). 765–7. 4 indexed citations
5.
Schraven, E, et al.. (1984). [Inhibition of monoamine oxidase A and B in the heart and brain of the rat with amitriptyline, pargyline and pirlindol].. PubMed. 34(10). 1258–60. 3 indexed citations
6.
Schraven, E, et al.. (1983). Inhibition of Vitamin D3-Induced Vascular Calcification by Carbocromen. PubMed. 4. 263–267. 6 indexed citations
7.
Schraven, E, et al.. (1982). Vitamin D-induced myocardial lesions and the protection by carbocromen.. PubMed. 32(11). 1412–7. 2 indexed citations
8.
Fromson, J. M., H. Paul A. Illing, R. M. J. Ings, et al.. (1981). Absorption and disposition of [14C]-molsidomine in laboratory animals.. PubMed. 31(2). 337–45. 7 indexed citations
9.
Schraven, E. (1978). Influence of carbocromene on free fatty acid metabolism of the heart.. PubMed. 11. 363–7. 4 indexed citations
10.
Schraven, E. (1976). [Regulation of lipid and carbohydrate metabolism of the heart by carbocromen (author's transl)].. PubMed. 26(2). 197–200. 5 indexed citations
11.
Schraven, E, et al.. (1976). [The effect of carbocromen on cardiac cyclic adenosine-monophosphate].. PubMed. 26(2). 200–4. 2 indexed citations
12.
Schraven, E, et al.. (1973). [Site of action of the coronary drug carbocromen].. PubMed. 91(19). 837–43.
13.
Schraven, E, et al.. (1972). [Studies on the distribution of carbochromen- 14 C in rats. Organ distribution and whole-body autoradiography after i.v. administration].. PubMed. 22(3). 479–87.
14.
Scholtholt, J, et al.. (1972). On the mechanism of the antagonistic action of xanthine derivatives against adenosine and coronary vasodilators.. PubMed. 22(8). 1255–9. 21 indexed citations
15.
Möllmann, H, et al.. (1972). [Pharmacodynamic studies after short- and long-term treatment with radioactively labelled 3-(beta-diethylamino-ethyl)-4-methyl-7-carbethoxy-2-oxo-(1,2-chromene)-hydrochloride in animal experiments].. PubMed. 22(8). 1242–50.
16.
Schraven, E, et al.. (1970). [Blood levels, distribution in the organs and excretion of carbochromen in rat, dog and man].. PubMed. 20(12). 1905–11. 2 indexed citations
17.
Schraven, E, et al.. (1968). Hemmung der Phosphodiesterase aus Rattenherzen durch Intensain. Cellular and Molecular Life Sciences. 24(4). 334–335. 7 indexed citations
18.
Schraven, E, et al.. (1967). Excretion, isolation and identification of the metabolites of Bisolvon®. European Journal of Pharmacology. 1(5). 445–451. 34 indexed citations
19.
Lembeck, F. & E Schraven. (1964). Der Einflu� von Hemicholinium Nr. 3 auf die Acetylcholin-Bildung in Lactobacillus arabinosus. Naunyn-Schmiedeberg s Archives of Pharmacology. 247(2). 93–99. 1 indexed citations
20.
Lingens, Franz & E Schraven. (1962). Synthesen von Amadori‐Verbindungen der Anthranilsäure. Justus Liebig s Annalen der Chemie. 655(1). 167–172. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026